Levothyroxine

number of adverse outcomes which occur during pregnancy and in the neonatal period in patients divided in Case Finding and Universal Screening groups

Incidence rate of pregnancy complications in women with or without thyroid antibodies

Birth of a living child beyond 28 weeks

Offspring neurocognitive assessment at 0-3 yrs

A composite of MACE within 4months after surgery

Health-Related Quality of Life (HRQOL) - Short Form 36 Physical Component Score

euthyroidism

Pregnancy rate

Change in Vasoactive Inotrope Score (VIS) score from beginning of active donor management until procurement.

Primary outcome measure was prevalence of recurrent goiter within the contralateral thyroid lobe

Psychological distress (depression or anxiety) assessed with HADS

Change of Serum Adiponectin from baseline

Proportion of participants who maintain discontinuation of levothyroxine for at least 6 months

Cognitive function evaluated by Bayley-IV

ThyPRO Scale Scores (0-100, Higher Scores Indicating Worse Quality of Life)

blood pressure

Percentage of patients achieving euthyroid status

% of TSH values within trimester-specific goal range per patient from study enrollment to delivery

Number of patients treated with Levothyroxine who develop pharyngocutaneous fistula after salvage laryngectomy

Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation

Changes in quality of life as measured with the ThyPro questionaire

Assessment of left ventricle systolic function

TSH after two weeks of TH substitution

Thyroid Stimulating Hormone as Primary Endpoint Measured at Initiation of Study, After 8 Weeks of One Drug, and Then 8 Weeks After the Second Drug.

Dose Adjustments

Changes in food intake at ad libitum meal

Change in working memory (N-back testing) and correlation with deiodinase type 2 polymorphism

High Angular Diffusion Tensor Imaging

The primary outcome measure is to compare the change in total volume of all nodules after 12 months Levothyroxin treatment to the change after 12 months of each of the reference treatments (one of the two active controls or placebo)

Thyroid-specific quality of life - Hypothyroid symptoms and Fatigue symptoms (co-primary outcomes)

Rate of First cardiovascular disorder (CVD) Events, CVD Mortality and All-cause Mortality

Change from baseline in 15-items Geriatric Depression Scale

Rate of fetal loss

change in lipid profile

Change from baseline in level of physical and mental fatigue as assessed by the Pittsburgh Fatigability Scale (PFS) score

Thyroid-Related Quality of Life Patient-Reported Outcome Quality of Life scale

Diastolic cardiac Function as measured by echocardiography

Carotid Intima Media Thickness as measured by carotid ultrasound

Executive Function

Change in bone mineral density (BMD)

Effects of an extra dose of L-thyroxine during the month of Ramadan

Rate of death weekly

(AUC) Area Under the Curve 0-48 for T4

Effects on gut inflammation parameter (Calprotectin)

Thyroid Stimulating Hormone (TSH)

Participants' Willingness to Enter the Trial

TSH suppression

Participant's acceptability of study design and willingness to enter study

LT4 Dose Required to Maintain TSH in Target Range (Unit: mcg/kg/Day)

Thyroid Stimulating Hormone changes

Maximum observed concentration (Cmax) and Area under concentration-time curve [AUC (0-48)]

Thyroid hormone-induced change in whole body insulin sensitivity (change in insulin-stimulated glucose disposal) and muscle mitochondrial function

Study feasibility

Number of Patients in Each Group at Predefined Target TSH Range at 18 Weeks

Tolerability as Assessed by the CareCAT Tool

Change of TSH

Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or Death.

Change in body weight (kg) from baseline to Month 3

Effect of the treatment of subclinical hypothyroidism on the apnea hypopnea index (AHI) score.

Change in Glasgow Coma Scale (GCS) From Intervention Initiation to ICU Discharge (Δ)

Hypothyroidism-free survival

Neurodevelopmental outcome

24 hours urine Proteinuria in patients with subclinical hypothyroidism and CKD G2-G5 without renal support therapy Randomized clinical trial of levothyroxine group versus placebo

Changes in Total Cholesterol

Change in cognitive ability measured by NEUROPSI increase of 10 points

Number of Participants With Overt Hypothyroidism

Change from baseline flow-mediated dilation at 2 months

Levothyroxine-to-ST-1891 dosing conversion factor

The ratio of the LT4 dose (mcg/day) at screening to North Star (mg/day) at the end of the treatment period required to achieve and maintain serum thyroid-stimulating hormone (TSH) levels within the normal reference range.

Percentage of Participants With a Sustained TSH Response

Percentage of Participants That Do Not Need a Change of Dose

ThyPRO Composite QOL Scale

Dose Conversion Factor

Liver fat content

Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase

Short Term Change in Weight

: Normalization of TSH.

Number of participants who receive Levothyroxine's vasopressor use compared to number of participants who receive normal saline's vasopressor use.

PK of EE and NET: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Last Quantifiable Concentration (AUC0-t)

AUCt of ambroxol

Baseline Corrected Maximum Observed Plasma Concentration (Cmax[Adj]) of Levothyroxine Sodium

Baseline-corrected area under the total T4 serum concentration-time curve from 0 to 48 hours after a single dose of levothyroxine

Bioequivalence

Bioequivalence

Bioequivalence

Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Levothyroxine (total T4)

Area under the concentration vs. time curve from zero to infinity after single (first) dose (AUC) of sorafenib

Gestational week at delivery

the score of Motivation subscale of the Negative Symptom Assessment (NSA-15)

Change in liver fat content

CL/F